Searched for
HEXAVALENT VACCINE
A Healthy Dialogue: Future of health sector cooperation under the Trump administrationIndia faces a complex health cooperation agenda with the incoming US administration. Key focus areas include trade in pharmaceuticals, pand...- Dispute with Sanofi settled, Panacea scrip soars to over 3-yr highPanacea Biotec has settled a patent dispute with Sanofi Healthcare India, leading to a rise in its stock. The Delhi High Court case involve...
- Panacea, Sanofi settle patent litigation over hexavalent vaccinePanacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Sh...
- Panacea Biotec gets $20 million loan from US government for hexavalent vaccine capacity expansionPanacea Biotec has secured a $20 million long-term loan from the US International Development Finance Corporation to expand its hexavalent ...
- DFC commits USD 20 mn long-term loan to Panacea BiotecUS International Development Finance Corporation has committed a long-term loan of up to USD 20 million to Panacea Biotec. The funds will h...
- Serum Institute signs deal with Aspen to sell vaccines in AfricaThe deal with Serum gives Aspen certainty on volumes, which will eventually more than cover an expected decline in revenues from its COVID ...
- Panacea Biotec files suit against Sanofi for patent infringement"The suit filed against Sanofi comes at the heels of Sanofi having received marketing approval for a Whole Cell Pertussis based Hexavalent ...
- Panacea Biotec partners Serum Institute for hexavalent vaccineThe vaccine is a combination of six antigens to protect against six dreaded diseases - Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemoph...
- Panacea Biotec says newly developed vaccine works better than its peersEasySixTM is a fully liquid ready-to-use hexavalent vaccine made using high quality antigens complying to WHO’s cGMP requirements."
- DCVMN International to quicken access to affordable vaccinesDCVMN International announced its intention to support the programme regarding access to affordable high quality vaccines.
- GSK in 50:50 JV with Biological E for developing paediatric vaccineThe vaccine would enable fewer injections for children thereby improving compliance in immunisation schedules.
- Our aim is to bring affordable vaccines to different regions: Harish Iyer, Shantha BiotechBarely two months into his new job after walking away as Biocon’s research head, Iyer echoes the language of a seasoned vaccine maker.
Load More
